Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02368314
Other study ID # BCD-080-2
Secondary ID
Status Recruiting
Phase Phase 3
First received February 5, 2015
Last updated February 16, 2015
Start date January 2015
Est. completion date January 2017

Study information

Verified date January 2015
Source Biocad
Contact Andrey Biryulin, MD
Phone (812) 380 49 33
Is FDA regulated No
Health authority Russia: Ministry of Health of the Russian Federation
Study type Interventional

Clinical Trial Summary

The purpose of the study is to prove equivalence of efficacy and safety of BCD-080 and Clexan for deep vein thrombosis and embolism prophylaxis at orthopedic surgeries.


Description:

The study will include 116 patients who are planned for hip or knee replacement. Patients will randomized in 2 groups. 1-st group will receive BCD-080 at dose 30 mg every 12 hours during 14 days after surgery, 2-d group will receive Clexane at the same dose. Efficacy assessment will include frequency of deep vein thrombosis (DVT) (proximal and/or distal; symptomatic or asymptomatic), symptomatic nonlethal thromboembolia of the pulmonary artery (PATE) and venous thromboembolism death. Safety assessment will include frequency of "big", "small" and other bleedings and frequency of heparin induced thrombocytopenia.The assessment of efficacy and safety parameters will be made during the treatment and follow-up period (till 60 day).


Recruitment information / eligibility

Status Recruiting
Enrollment 116
Est. completion date January 2017
Est. primary completion date January 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Written informed consent

2. Age =18 years and age =80 years

3. Women body mass 50-110kg, men body mass 57-110 kg inclusive

4. Patients who are planned for hip or knee replacement

5. Willingness of patients of both sexes and their sexual partners with preserved reproductive function to use reliable methods of contraception, starting from screening and up to 4 weeks after the last dose of the studied drug. This requirement does not apply to patients who underwent surgical sterilization. Reliable methods of contraception involves a 1-barrier method combined with one of the following: spermicides/oral contraceptive

6. Ability of the patient, in the opinion of the investigator, to meet the Protocol requirements.

Exclusion Criteria:

1. Hypersensitivity to the components included in the formula of preparation BCD-080 (CJSC BIOCAD) Clexane (Sanofi-Avensis France, France) or medications of the same class

2. Conditions and diseases in which there is a high risk of bleeding: cerebral aneurysm or aortic dissection, hemorrhagic stroke (including in history)

3. Intractable hemorrhage

4. History of documented diseases of blood coagulation (hemophilia A or B, Willebrand disease and other coagulopathies, idiopathic thrombocytopenic purpura, Heparin induced thrombocytopenia associated with thrombosis or without it, thrombohemorrhagic syndrome, etc.) in anamnesis and/or at the moment of examination

5. Gastric or duodenal ulcer or other erosive and ulcerative lesions of gastrointestinal tract

6. Recent ischemic stroke

7. Uncontrolled severe hypertension; that is, all cases of hypertension, in which blood pressure decrease cannot be achieved with the use of combination of 3 antihypertensive drugs, compulsorily including a diuretic, and non-drug methods of correction (salt-free diet, graduated exercise); or if the results of two successive measurements of supine arterial blood pressure with an interval of 15-30 minutes, systolic blood pressure> 180 mm Hg. or diastolic blood pressure> 105 mm Hg

8. Diabetic or hemorrhagic retinopathy

9. Decompensated diabetes mellitus, diabetes mellitus complications

10. Recent delivery (during last 90 days)

11. Bacterial endocarditis (acute or subacute)

12. Pericarditis and pericardial effusion

13. Renal and/or hepatic insufficiency

14. Intrauterine contraception

15. Surgeries or injuries of brain/spinal cord, spine, eyes, and major surgeries and injuries within 90 days prior to randomization)

16. Spinal surgeries or its deformation in history of patients who are planned for epidural/spinal anesthesia

17. Active liver diseases

18. Anamnestic information about alcoholism, addiction or drug abuse over the last year

19. Contraindications to surgeries

20. Hemoglobin <100 g/l

21. Platelet count <100?10*9/l

22. Creatine clearance <30 ml/min

23. Biochemical blood assay indexes: AST/ALT > UNL?3; total bilirubin > UNL?1,5 (unless other causal factors provided, such as Gilbert's syndrome)

24. Necessity for continued treatment with anticoagulants (except for planned under this study), antiaggregant and fibrinolytics (eg, patients with artificial cardiac valve, atrial fibrillation patients receiving warfarin, etc.)

25. The use of dextrans or fibrinolytic therapy or other drugs affecting hemostasis;

26. Necessity for use of systemic glucocorticosteroids and non-steroidal anti-inflammatory drugs (except for the use of the latter with the purpose of anaesthesia in the early postoperative period - during 3 days after the planned hip or knee replacement)

27. Impossibility of contrast venography: contrast allergy, inability to install an intravenous catheter, etc

28. Pregnancy, lactation period

29. Donation of 450 ml or more of blood or plasma within 60 calendar days before inclusion enrolment

30. Participation in clinical trials no less than 30 days before enrolment into this study or previous participation in this clinical study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Sodium Enoxaparine
30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).

Locations

Country Name City State
Russian Federation Railroad Clinical Hospital at the station Chelyabinsk Chelyabinsk

Sponsors (1)

Lead Sponsor Collaborator
Biocad

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of DVT. Frequency of deep vein thrombosis (DVT) (proximal and/or distal; symptomatic or asymptomatic). During the treatment period (14 days) No
Primary Frequency of symptomatic nonlethal thromboembolia of the pulmonary artery (PATE) During the treatment period (14 days) No
Primary Frequency of venous thromboembolism death During the treatment period (14 days) No
Secondary Frequency of DTV Frequency of DTV (proximal and/or distal; symptomatic or asymptomatic) During the treatment period (14 days) and follow-up period (till 60-th day) No
Secondary Frequency of proximal DVT Frequency of proximal DVT (symptomatic or asymptomatic) During the treatment period (14 days) and follow-up period (till 60-th day) No
Secondary Frequency of distal DVT Frequency of distal DVT (symptomatic or asymptomatic) During the treatment period (14 days) and follow-up period (till 60-th day) No
Secondary Frequency of symptomatic nonlethal PATE During the treatment period (14 days) and follow-up period (till 60-th day) No
Secondary Frequency of venous thromboembolism death During the treatment period (14 days) and follow-up period (till 60-th day) No
Secondary Frequency of death from other causes During the treatment period (14 days) and follow-up period (till 60-th day) No
Secondary Frequency of venous thromboembolism (PATE and/or DTV) During the treatment period (14 days) and follow-up period (till 60-th day) No
Secondary Frequency of "big" and clinically significant "small" bleedings During the treatment period (14 days) Yes
Secondary Frequency of "big" bleedings During the treatment period (14 days) Yes
Secondary Frequency of clinically significant "small" bleedings During the treatment period (14 days) Yes
Secondary Frequency of clinically significant bleedings During the treatment period (14 days) Yes
Secondary Frequency of other "small" bleedings During the treatment period (14 days) Yes
Secondary Frequency of all bleedings During the treatment period (14 days) Yes
Secondary Frequency of heparin induced thrombocytopenia During the treatment period (14 days) Yes
Secondary Frequency of strokes, myocardial infarction, unstable angina and cardiovascular death During the treatment period (14 days) and follow-up period (till 60-th day) Yes
Secondary Frequency of other AE SAE During the treatment period (14 days) and follow-up period (till 60-th day) Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05003843 - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis N/A
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters N/A
Completed NCT03420625 - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02555111 - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Phase 3
Completed NCT01975090 - The SENTRY Clinical Study N/A
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT02037607 - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Completed NCT00264277 - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Phase 4
Completed NCT00365950 - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Phase 4
Completed NCT00182403 - Fixed Dose Heparin Study Phase 3
Completed NCT03682419 - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) N/A
Not yet recruiting NCT04981327 - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis Phase 3
Recruiting NCT03240120 - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism Phase 3

External Links